Barclays PLC Cuts Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 1,500
Hikma Pharmaceuticals Plc (LON:HIK) had its price target reduced by Barclays PLC from GBX 2,200 ($28.56) to GBX 1,500 ($19.47) in a report released on Friday. They currently have an overweight rating on the stock.
Several other analysts have also commented on the stock. Citigroup Inc. reiterated a neutral rating and issued a GBX 1,350 ($17.53) price target on shares of Hikma Pharmaceuticals Plc in a research report on Thursday. Goldman Sachs Group, Inc. (The) lowered shares of Hikma Pharmaceuticals Plc to a neutral rating and lowered their price target for the company from GBX 2,600 ($33.75) to GBX 1,310 ($17.01) in a research report on Tuesday, August 22nd. Morgan Stanley lowered shares of Hikma Pharmaceuticals Plc to an equal weight rating and lowered their price target for the company from GBX 1,600 ($20.77) to GBX 1,350 ($17.53) in a research report on Monday, August 21st. Jefferies Group LLC lowered their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.04) to GBX 1,045 ($13.57) and set a hold rating on the stock in a research report on Monday, August 21st. Finally, Numis Securities Ltd reiterated an add rating and issued a GBX 1,560 ($20.25) price target on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of GBX 1,686 ($21.89).
Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1288.00 on Friday. Hikma Pharmaceuticals Plc has a one year low of GBX 1,101.00 and a one year high of GBX 2,346.00. The company’s market cap is GBX 3.09 billion. The company has a 50 day moving average price of GBX 1,345.28 and a 200 day moving average price of GBX 1,733.12.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.